| (Values in U.S. Thousands) | Jun, 2026 | Mar, 2026 | Jun, 2025 | Mar, 2025 | Mar, 2025 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -111,310 | -78,870 | -28,950 | -17,980 | 0 |
| Net Income Growth | -41.13% | -172.44% | -61.01% | unch | unch |
Kailera Therapeutics Inc (KLRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Kailera Therapeutics Inc. is an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care. Kailera Therapeutics Inc. is based in WALTHAM, Mass.
Fiscal Year End Date: 12/31